Vir Biotechnology, Inc. (VIR) — SEC Filings

Latest SEC filings for Vir Biotechnology, Inc. (VIR), explained in plain English.

Sentiment Overview: 1 bullish, 4 bearish, 30 neutral

Recent Filings (35)

• Vicki Sato Reports Vir Biotechnology Security Changes — 4 · 2026-04-02T10:46:41-04:00 [neutral] Risk: low
  On April 1, 2026, Vicki L. Sato reported a change in beneficial ownership of securities for Vir Biotechnology, Inc. The filing, dated April 2, 2026, details tra
• 8-K Filing — 8-K · 2025-12-16T00:00:00.000Z [neutral]
• Vir Bio Narrows Q3 Loss to $163M Amid Revenue Dip, R&D Cuts — 10-Q · 2025-11-05T00:00:00.000Z [bearish] Risk: high
  Vir Biotechnology, Inc. reported a significant net loss of $163.1 million for the three months ended September 30, 2025, an improvement from the $213.7 million
• Vir Bio's Revenue Plummets 90% Amid Collaboration Wind-Down — 10-Q · 2025-08-06T00:00:00.000Z [bearish] Risk: high
  Vir Biotechnology, Inc. reported a significant decrease in total revenue for the three and six months ended June 30, 2025, primarily due to reduced collaboratio
• Vir Biotechnology Files 8-K — 8-K · 2025-07-24T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on July 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific de
• Vir Biotechnology Files 8-K on Security Holder Votes — 8-K · 2025-05-29T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not disclose specific de
• Vir Biotechnology Files 8-K — 8-K · 2025-05-09T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on May 9, 2025, reporting other events and financial statements. The filing details the company's principal executive offic
• Vir Biotechnology Files Q1 2025 10-Q Report — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed its Q1 2025 10-Q report on May 8, 2025, for the period ending March 31, 2025. The company, based in San Francisco, CA, operates in
• Vir Biotechnology Files 8-K on Financials — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on May 7, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibit
• Vir Biotechnology DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-17T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed a DEF 14A on April 17, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board mem
• 10-K Filing — 10-K · 2025-02-27T00:00:00.000Z [neutral]
• Vir Biotechnology Files 8-K on Financials — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Vir Biotechnology Announces Board and Executive Changes — 8-K · 2025-01-30T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. announced on January 24, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company repo
• Vir Biotechnology Files 8-K — 8-K · 2025-01-08T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on January 8, 2025, reporting on events including a Regulation FD Disclosure, other events, and financial statements/exhibi
• Vir Biotechnology Files Q3 2024 10-Q — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business
• Vir Biotechnology Files 8-K on Financials — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on October 31, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• SC 13G/A Filing — SC 13G/A · 2024-10-18T00:00:00.000Z [neutral]
• Vir Biotechnology Director Departs Board — 8-K · 2024-09-10T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. announced on September 6, 2024, the departure of Dr. George Yancopoulos from its Board of Directors. Dr. Yancopoulos, who also served as
• Vir Biotechnology Enters Material Definitive Agreement — 8-K · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  On July 31, 2024, Vir Biotechnology, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement, suc
• Vir Biotechnology 10-Q: Q2 2024 Update — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from collaborations and contracts, with specific figure
• Vir Biotechnology Files 8-K — 8-K · 2024-06-26T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements/exhibits. The filing does not detail specific transaction
• Vir Biotechnology Files 8-K — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on June 5, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Vir Biotechnology Files 8-K on Security Holder Vote — 8-K · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on May 29, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific det
• Vir Biotechnology Files Proxy Materials for 2024 Annual Meeting — DEFA14A · 2024-05-14T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed a Definitive Additional Materials (DEFA14A) on May 14, 2024, related to its 2024 Annual Meeting and Stockholder Engagement efforts
• Vir Biotechnology Q1 Revenue Surges on Collaboration Deals — 10-Q · 2024-05-03T00:00:00.000Z [bullish] Risk: medium
  Vir Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported collaboration revenue of $104.7 million for the three months e
• Vir Biotechnology Files 8-K on Operations and Financials — 8-K · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed an 8-K on May 2, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibit
• Vir Biotechnology Files Proxy Statement for 2024 Annual Meeting — DEF 14A · 2024-04-19T00:00:00.000Z [neutral] Risk: low
  Vir Biotechnology, Inc. filed its definitive proxy statement on April 19, 2024, for its annual meeting of stockholders scheduled for May 29, 2024. The filing ou
• Vir Biotechnology Files 8-K on Executive and Board Changes — 8-K · 2024-04-18T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. filed an 8-K on April 18, 2024, reporting on events as of April 15, 2024. The filing covers the departure of directors or certain office
• Vir Biotech's Revenue Plummets 80% in 2023, Net Loss Widens — 10-K · 2024-02-26T00:00:00.000Z [bearish] Risk: high
  Vir Biotechnology, Inc. reported a significant decrease in total revenues for the fiscal year ended December 31, 2023, dropping to $104.9 million from $517.2 mi
• Vir Biotechnology Files 8-K on Material Agreement & Financials — 8-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 21, 2024. The filing indicates an entry into a material
• Vir Biotechnology Files 8-K on Officer Changes & Compensation — 8-K · 2024-02-20T00:00:00.000Z [neutral] Risk: medium
  Vir Biotechnology, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 19, 2024. The filing pertains to Item 5.02, specifically
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• State Street Corp. Discloses Passive Stake in Vir Biotechnology — SC 13G · 2024-01-24T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, reported an initial filing on January 24, 2024, disclosing its ownership of Vir Biotechnology, Inc. com
• BlackRock Cuts Vir Biotechnology Stake to 4.3% — SC 13G/A · 2024-01-23T00:00:00.000Z [bearish]
  BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Vir Biotechnology, Inc. As of December 31, 2023, BlackRock holds 5,744